Trial reportScience advances2022
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8.
Open access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 148 citations in OpenAlex.
- Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.Molecular cancer · 2026Trial
- Superior tumor cell killing by oxygen ion beam irradiation compared to carbon ions and photons in pancreatic Cancer cells - An in vitro investigation.Clinical and translational radiation oncology · 2026Article
- Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy.The Journal of clinical investigation · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements.Molecular carcinogenesis · 2026Review
- Non-coding RNAs (ncRNAs)-mediated high expression of Ras-related C3 botulinum toxin substrate 1 (RAC1) correlates with poor prognosis and tumor immune infiltration of liver hepatocellular carcinoma.Translational cancer research · 2026Article
- Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice.Nature communications · 2026Article
- Mapping the research landscape of the correlation between radiotherapy and tumor immune microenvironment: A bibliometric analysis.Precision radiation oncology · 2026Article
- Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosis.Signal transduction and targeted therapy · 2026Article
- Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features.Frontiers in oncology · 2026Article
- Combining advanced radiotherapy techniques and immunotherapy: immunomodulatory mechanisms and clinical prospects.Frontiers in immunology · 2026Review
- The Implications of Radiotherapy-Induced Cellular Senescence for Cancer Treatment and Tumor Microenvironment Modulation.International journal of biological sciences · 2026Review
- Advances in neoadjuvant immunotherapy for non-small cell lung cancer.Frontiers in immunology · 2026Review
- FKBP10 promotes M2 polarization of macrophage via MEK/ERK/CXCL8 axis and facilitates tumor progression in clear cell renal cell carcinoma.International journal of biological sciences · 2026Article
- Beyond local control: radiotherapy-immunotherapy combinations fromFrontiers in genetics · 2026Review
- Implications of DNA damage response and immunotherapy in tumor therapy.Cell communication and signaling : CCS · 2025Review
- Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7Oncoimmunology · 2025Article
- Radiation-Induced Immune Responses from the Tumor Microenvironment to Systemic Immunity.Cancers · 2025Review
- Identification of CXCL8 as a potential gene associated with lymph node metastasis in papillary thyroid carcinoma through bioinformatics analysis.Scientific reports · 2025Article
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 6 institutions in 2 countries.
Thomas WalleDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4835-955X
Joscha A KraskeDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8567-6020
Boyu LiaoDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bénédicte LenoirClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany.
Carmen TimkeDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-0256-6625
Emilia von Bohlen Und HalbachDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Florian TranInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-3735-9872
Paul GriebelInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.ORCID 0000-0001-5671-8183
Dorothee AlbrechtDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4821-1005
Azaz AhmedDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.ORCID 0000-0003-3000-7951
Meggy Suarez-CarmonaClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-8892-1546
Alejandro Jiménez-SánchezProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1879-7057
Tizian BeikertDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alexandra Tietz-DahlfußDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-1489-3885
Ayse Nur MenevseLeibniz Institute for Immunotherapy, Division of Interventional Immunology, Regensburg, Germany.ORCID 0000-0002-6024-3464
Gabriele SchmidtCore Facility Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Manuela BromCore Facility Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jens H W PahlDepartment of Immunobiochemistry and MI3, Mannheim Institute for Innate Immunoscience, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany.
Wiebke AntonopoulosInstitute of Pathology University Hospital Heidelberg, Heidelberg, Germany.
Matthias MillerDepartment of Immunobiochemistry and MI3, Mannheim Institute for Innate Immunoscience, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany.
Ramon Lopez PerezDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-6876-2074
Felix BestvaterCore Facility Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nathalia A GieseDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Philipp BeckhoveLeibniz Institute for Immunotherapy, Division of Interventional Immunology, Regensburg, Germany.ORCID 0000-0002-0099-5576
Philip RosenstielInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-9692-8828
Dirk JägerDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Oliver StrobelDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Dana Pe'erParker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9259-8817
Niels HalamaDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Jürgen DebusDepartment of Radiooncology and Radiotherapy, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-6411-4811
Adelheid CerwenkaDepartment of Immunobiochemistry and MI3, Mannheim Institute for Innate Immunoscience, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany.ORCID 0000-0001-6977-3536
Peter E HuberDepartment of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4811-300X
German Cancer Research Center · DEHeidelberg University · DEUniversity of Mannheim · DEChristian-Albrechts-Universität zu Kiel · DELeibniz Association · DEMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T cell responses. However, the role of Natural Killer (NK) cells in radiotherapy remains unclear. Here, using a reverse translational approach, we show a central role of NK cells in the radiation-induced immune response involving a CXCL8/IL-8-dependent mechanism. In a randomized controlled pancreatic cancer trial, CXCL8 increased under radiotherapy, and NK cell positively correlated with prolonged overall survival. Accordingly, NK cells preferentially infiltrated irradiated pancreatic tumors and exhibited CD56
Indexed as
Interleukin-8Killer Cells, NaturalNeoplasmsAdoptive TransferAnimalsHumansImmunityMiceXenograft Model Antitumor AssaysCXCL8 protein, humanInterleukin-8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.